New agent strikes at respiratory syncytial virus replication

University of Texas Medical Branch at Galveston researchers have achieved promising results with a potential new weapon against respiratory syncytial virus, the most common cause of infant hospitalization in the United States.

In an effort to find an effective antiviral therapy for RSV, the scientists tested two types of complex, custom-designed molecule to interfere with the genetic machinery that RSV uses to replicate, or copy itself, within cells. Both of the so-called “morpholino oligomers,” created by Oregon-based AVI BioPharma, penetrated cultured human airway cells easily and produced only minimal toxicity. One of the two, designated AUG-2, significantly reduced RSV replication in both cell culture and mouse experiments.

“Viral replication is one of the major pathogenetic processes of RSV, and we badly need a specific antiviral therapy,” said UTMB Dr. Roberto Garofalo, senior author of a paper on the study to be published in the June issue of Molecular Therapy and now available in the “Advance Online Publication” section of the journal’s website. “That's what an agent like this morpholino could give us.”

RSV infects almost all children by age two, but normally causes only a cold-like upper respiratory infection. In some babies, however, it spreads to the lungs, where the inflammation it generates causes coughing, wheezing and extreme difficulty in breathing, a life-threatening clinical syndrome known as bronchiolitis.

Recent research by Garofalo and other investigators suggests that two key factors drive RSV bronchiolitis: an inflammatory overreaction by the cells that line the airways of the lungs, and a failure to respond to RSV by T lymphocytes (also known as “T cells”), immune system cells that ordinarily act to control viral infections.

Because a dangerous inflammatory response occurs so soon after RSV begins replicating in the lungs, Garofalo said, antiviral therapy by itself is unlikely to be sufficient to treat severe RSV infection in infants. But it could be a critical part of a “combination therapy” that also included drugs to reduce RSV-induced lung inflammation and boost T-cell response.

“The virus continues to replicate for days in the lungs of infected infants, and it induces inflammation as long as it replicates,” Garofalo said. “So stopping viral replication would be a very important part of any therapeutic strategy for RSV.”

Source: University of Texas

Related stories:

Weak immune response critical to disease that causes most infant hospitalizations
The most common cause of infant hospitalization in the United States, respiratory syncytial virus, infects virtually all children by age two. Along with the influenza virus, RSV is a major contributor to the approximately two million infant deaths worldwide caused every year by respiratory infections, according to the World Health Organization. Worse yet, there’s no safe and effective RSV vaccine available to prevent severe respiratory infections, and no specific antiviral therapy to treat them.
Researchers use laser, nanotechnology to rapidly detect viruses
Waiting a day or more to get lab results back from the doctor's office soon could become a thing of a past. Using nanotechnology, a team of University of Georgia researchers has developed a diagnostic test that can detect viruses as diverse as influenza, HIV and RSV in 60 seconds or less.
Molecular imaging may lead to earlier diagnosis of childhood respiratory virus
Scientists have used a powerful molecular imaging technique to see inside living cells infected with the most pervasive and potentially fatal childhood respiratory virus known to medicine -- respiratory syncytial virus (RSV). The technique is yielding insight on viruses – such as RSV, human influenza, hepatitis C, West Nile virus and severe acute respiratory syndrome (SARS) -- that replicate with the help of proteins encoded by ribonucleic acid (RNA) inside the cell. Ultimately, the research could to lead to early and rapid detection of viral infection and the design of new antiviral drugs.
Quantum dots detect viral infections
In what may be one of the first medical uses of nanotechnology, a chemist and a doctor who specializes in infectious childhood diseases have joined forces to create an early detection method for a respiratory virus that is the most common cause of hospitalization among children under five.
McMaster test detects the most prevalent respiratory viruses
Diagnosing a nasty cough is now a lot easier thanks to a new test developed at McMaster University, which has just been approved by U.S. Food and Drug Administration (FDA) for use in the United States.
Scientists find predisposition to bronchiolitis in some babies
Scientists have found that a large proportion of infants who suffer from bronchiolitis have an inherent pre-disposition to the disease.
RNAi shows promise in gene therapy, researcher says
Three years ago Mark Kay, MD, PhD, published the first results showing that a biological phenomenon called RNA interference could be an effective gene therapy technique. Since then he has used RNAi gene therapy to effectively shut down the viruses that cause hepatitis and HIV in mice.

News discussion:

Medicine & Health news